Suresh Rav focuses his practice on patent litigation. His technical experience and education span the areas of biochemistry, physics, organic chemistry, microbiology, and physiology.
View profileUnder 35 U.S.C. § 311(b), a Petitioner may seek to institute an IPR on grounds that “could be raised under section 102 or 103 and only on the basis of prior art consisting of patents or printed public...
Overview On July 6, 2020, the Federal Circuit affirmed denial of Genentech’s motions to enjoin Amgen from marketing MVASI™ (bevacizumab-awwb), a biosimilar version of Genentech’s AVASTIN® (bevacizumab...
In spite of social distancing requirements established by the COVID-19 pandemic, courts are now more likely to expect that litigants have been diligently keeping up with various pretrial tasks. While ...